ArticleFrontiers in immunology2025
Piezo1 protects against inflammatory bone loss via a unique Ca
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trained immunity in inflammatory bone disease: a bibliometric and literature-level text-mining analysis.Frontiers in immunology · 2026Pooled it
- Reprogramming bone homeostasis: The recoupling-oriented framework of bidirectional regulation strategies for osteoporosis.iScience · 2026Review
- Engineering Piezo1-Mediated Calcium Signalling for Enhanced Extracellular Vesicle Biogenesis and Cargo Loading.Journal of extracellular biology · 2026Article
- Piezo1-mediated Mechanotransduction in the musculoskeletal system: Signaling networks and therapeutic perspectives.Bone reports · 2026Review
- Signalling Pathways and Mechanical Forces Interact in Craniofacial Development and Homeostasis.International dental journal · 2026Review
- Piezo1, Integrins, and YAP/TAZ in Osteoporotic Mechanotransduction: Key Pathways, Crosstalk, and Therapeutic Implications.Calcified tissue international · 2026Review
- Adjunct Tendon Vibration and Bone Outcomes in Older Adults with Osteoporosis: A 12-Month Prospective Cohort Study.Journal of clinical medicine · 2026Article
- Yoda molecules agonize PIEZO2.bioRxiv : the preprint server for biology · 2026Article
- Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Spectrum and functions of ion channels and transporters in osteoclasts.Bone research · 2026Review
- The Role of Wnt Signaling in Age-Related Alveolar Bone Loss and Regeneration.Journal of periodontal research · 2026Review
- Article
- Piezo1-mediated mechanotransduction and metabolic regulation in bone health: molecular mechanisms and implications for bone disorders.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Introduction: Bone integrity relies on mechanical stimulation, and its absence, such as in disuse osteoporosis or periodontitis, enhances osteoclast-mediated resorption. Although Piezo1 is a well-characterized mechanosensitive ion channel in several cell types, its function in osteoclast lineage cells has remained unclear. Methods: We examined Piezo1 expression and signaling in pre-osteoclasts (OCs) using mouse models of periodontal bone loss and in vitro differentiation assays. Genetic and pharmacological approaches were applied to manipulate Piezo1 activity. Downstream pathways were assessed with a focus on NFATc1 regulation, Akt phosphorylation, and PP2A activity. The therapeutic potential of the Piezo1 agonist Yoda1 was tested in inflammatory bone loss models. Results: Piezo1 was selectively expressed and functional in pre-OCs, where it acted as a mechanosensor to inhibit RANKL-induced OC-genesis. Activation of Piezo1 suppressed NFATc1 via a Ca Discussion: Our findings redefine Piezo1 as a critical mechanosensor in pre-OCs and establish the Piezo1-PP2A-Akt axis as a novel regulator of NFATc1-driven OC-genesis. These results provide a mechanistic explanation for bone resorption in mechanically compromised states and highlight Piezo1 activation as a therapeutic strategy to mimic mechanical cues and suppress pathological OC-genesis in conditions such as periodontitis, rheumatoid arthritis, and osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.